Cite
HARVARD Citation
O'Donnell, P. et al. (2020). Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108. Cancer. 126 (2), pp. 432-443. [Online].